Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Nucleoside analogues: first line herpes antivirals
3. Phosphorylation of acyclic nucleoside analogues
4. Acyclovir (zovirax)
5. Mechanism of action of acyclovir
6. Pharmacokinetics of acyclovir and valacyclovir
7. Toxicities of acyclovir and valacyclovir
8. Antiviral resistance
9. Clinical application of acyclovir
10. Clinical application continued
11. Herpes gingivostomatitis/labialis
12. First episode or recurrent genital herpes
13. Severe HSV disease: IV high-dose acyclovir
14. Varicella zoster
15. Other anti-HSV drugs
16. Anti-CMV drugs: ganciclovir and valganciclovir
17. Mechanism and pharmacokinetics of ganciclovir
18. Toxicities of ganciclovir
19. Ganciclovir resistance
20. Clinical indications for ganciclovir
21. CMV retinitis in AIDS
22. Alternative anti-herpes drugs: foscarnet (foscavir)
23. Foscarnet: pharmacokinetics and toxicities
24. Foscarnet: resistance and clinical indications
25. Cidofovir (vistide)
26. Cidofovir: pharmacokinetics and toxicities
27. Cidofovir: clinical indications and resistance
28. Fomivirsen (vitravene)
29. Influenza: orthmyxoviridae family
30. Antiviral targets in influenza
31. Anti-viral drugs for prevention/treatment of influenza
32. Anti-influenza drugs: M2 inhibitors (1)
33. Anti-influenza drugs: M2 inhibitors (2)
34. Anti-influenza drugs: neuraminidase inhibitors
35. Oseltamivir pharmacokinetics and toxicities
36. Oseltamivir: clinical indications
37. Oseltamivir vs. placebo in normal adults
38. Time to symptom resolution in flu-infected patients
39. Six week prevention trial: community flu outbreak
40. Anti-hepatitis B drugs
41. Lamivudine for HBV - toxicities and resistance
42. Lamivudine for hepatitis B - clinical indications
43. Adefovir dipivoxil (hepsera)
44. Adefovir dipivoxil - pharmacokinetics, resistance
45. Adefovir dipivoxil (hepsera) - clinical indications
46. Entecavir: hepatitis B antiviral
47. Entecavir continued...
48. Resistance rates: lamivudine, hepsera, entecavir
49. Recombinant interferon alpha
50. Recombinant interferon
51. Recombinant interferon - clinical indications (1)
52. Recombinant interferon - clinical indications (2)
53. Ribavirin: role in HCV infection
54. Ribavirin
55. Conclusions

Topics Covered

• Pharmacokinetics and clinical application of antiviral agents excluding antiretrovirals for HIV
• The therapeutic and prophylactic options for herpes infections including herpes simplex 1 and 2, varicella zoster and cytomegalovirus
• Therapeutic and prophylactic agents for influenza
• Approved agents for the treatment of hepatitis B and C

Links

Series:

• Viruses and Viral Diseases

Categories:

• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on March 15, 2018

Financial Disclosures

• Prof. Mary Klotman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.